These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Filmont JE; Czernin J; Yap C; Silverman DH; Quon A; Phelps ME; Emmanouilides C Chest; 2003 Aug; 124(2):608-13. PubMed ID: 12907550 [TBL] [Abstract][Full Text] [Related]
43. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Musso M; Messina G; Di Renzo N; Di Carlo P; Vitolo U; Scalone R; Marcacci G; Scalzulli PR; Moscato T; Matera R; Crescimanno A; Santarone S; Orciuolo E; Merenda A; Pavone V; Pastore D; Donnarumma D; Carella AM; Ciochetto C; Cascavilla N; Mele A; Lanza F; Di Nicola M; Bonizzoni E; Pinto A Br J Haematol; 2016 Jan; 172(1):111-21. PubMed ID: 26458240 [TBL] [Abstract][Full Text] [Related]
44. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527 [TBL] [Abstract][Full Text] [Related]
45. Prognostic Value of 2-Deoxy-2-[ Dai N; Zhou Y; Deng S; Sang S; Wu Y Contrast Media Mol Imaging; 2021; 2021():5510825. PubMed ID: 33958977 [TBL] [Abstract][Full Text] [Related]
46. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779 [TBL] [Abstract][Full Text] [Related]
47. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139 [TBL] [Abstract][Full Text] [Related]
48. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382 [TBL] [Abstract][Full Text] [Related]
49. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma. Driessen J; Zwezerijnen GJC; Schöder H; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Heymans MW; Boellaard R; Zijlstra JM Blood Adv; 2023 Nov; 7(21):6732-6743. PubMed ID: 37722357 [TBL] [Abstract][Full Text] [Related]
50. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
51. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Crocchiolo R; Canevari C; Assanelli A; Lunghi F; Tassara M; Stanghellini ML; Clerici D; Landoni C; Servida P; Bernardi M; Peccatori J; Ferreri A; Gianolli L; Bordignon C; Caligaris-Cappio F; Ciceri F; Fazio F Leuk Lymphoma; 2008 Apr; 49(4):727-33. PubMed ID: 18398740 [TBL] [Abstract][Full Text] [Related]
52. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Shafey M; Duan Q; Russell J; Duggan P; Balogh A; Stewart DA Leuk Lymphoma; 2012 Apr; 53(4):596-602. PubMed ID: 21929284 [TBL] [Abstract][Full Text] [Related]
53. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246 [TBL] [Abstract][Full Text] [Related]
54. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941 [TBL] [Abstract][Full Text] [Related]
55. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
56. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT? Hertzberg M Hematol Oncol Clin North Am; 2014 Feb; 28(1):123-47. PubMed ID: 24287072 [TBL] [Abstract][Full Text] [Related]
57. Prognostic value of pre- and post-transplantation Ying Z; Mi L; Wang X; Zhang Y; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J Chin J Cancer Res; 2017 Dec; 29(6):561-571. PubMed ID: 29353979 [TBL] [Abstract][Full Text] [Related]
58. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908 [TBL] [Abstract][Full Text] [Related]
59. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]
60. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Onishi M; Graf SA; Holmberg L; Behnia S; Shustov AR; Schiavo K; Philip M; Libby EN; Cassaday RD; Pagel JM; Roden JE; Maloney DG; Green DJ; Till BG; Press OW; Smith SD; Gopal AK Hematol Oncol; 2015 Dec; 33(4):187-91. PubMed ID: 25236531 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]